The regulator has approved Keytruda as monotherapy and also in combination with a commonly used chemotherapy regimen – platinum and fluorouracil (FU). The approval is for first-line treatment
The post FDA extends approval of Merck’s Keytruda in head and neck cancer appeared first on Pharmaceutical Business review.
Original Article: FDA extends approval of Merck’s Keytruda in head and neck cancer